**ADMA Biologics Reports Strong Revenue Growth and Achieves Profitability in Fiscal Year 2025**

ADMA Biologics, Inc., a biopharmaceutical company specializing in plasma-derived biologics, announced its financial results for the year ended December 31, 2025, showcasing significant revenue growth and continued profitability. The company reported total revenues of $510.2 million, a 20% increase compared to $426.5 million in 2024. This growth was primarily driven by a surge in sales of ASCENIV, which increased by 51% to $362.5 million, reflecting increased physician, payer, and patient acceptance. BIVIGAM sales decreased by 14% to $122.0 million, while intermediates and other product revenues decreased by 75% to $8.6 million. The Plasma Collection Centers segment also experienced growth, with revenues increasing by 62% to $17.0 million.

The company's financial performance also saw a significant improvement in gross profit, which increased to $292.8 million, resulting in a gross margin of 57.4%, compared to $219.6 million and a 51.5% gross margin in the previous year. This improvement was attributed to a more favorable mix of higher-margin IVIG sales and a reduction in manufacturing costs. Operating expenses increased to $101.3 million, primarily due to higher selling, general, and administrative expenses related to increased headcount and business expansion. Despite the increase in operating expenses, income from operations rose to $191.4 million, compared to $139.0 million in the prior year.

Strategic developments during the year included the FDA approval of a yield enhancement production process for ASCENIV and BIVIGAM, expected to increase production yields by 20% or more. The company also acquired real estate in Boca Raton, FL, for $12.6 million to expand production operations and storage capabilities. Additionally, ADMA Biologics entered into an agreement to divest three plasma collection centers for $12.0 million, while securing long-term plasma supply agreements with the purchaser. These strategic moves are expected to improve capital efficiency and support increased ASCENIV production capacity.

Looking ahead, ADMA Biologics anticipates continued growth in ASCENIV sales and sustained margin expansion due to the yield enhancement production process. The company also expects to receive potential FDA approval for the expansion of ASCENIV's label to include the pediatric setting in the first half of fiscal year 2026. Furthermore, ADMA Biologics is progressing with the development of its S. pneumoniae hyperimmune globulin program, SG-001, with plans to submit a pre-Investigational New Drug (IND) package to the FDA in fiscal year 2026. The company's employee headcount as of December 31, 2025, was 647, with plans to hire additional personnel in compliance, production, quality assurance, sales, and administration.

About ADMA BIOLOGICS, INC.

ADMA Biologics, Inc. is a biopharmaceutical company specializing in the development and commercialization of plasma-derived therapeutics for immunocompromised patients. Its key products include ASCENIV and BIVIGAM, both FDA-approved intravenous immune globulin therapies. With a growing market projected to exceed $20 billion by 2030, ADMA targets patients with primary immunodeficiency diseases. The company is innovating with a yield enhancement process and expanding its product pipeline to address unmet medical needs.

This description was generated via AI from an annual report. Updated 9 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.